NCT01635855已完成4 期
Belotero® Post Approval Study for the Treatment of Nasolabial Folds
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 117
- 试验地点
- 9
- 主要终点
- Rate of Severe Common Adverse Events
研究概览
简要总结
A prospective, open-label 1-month post-approval study to evaluate the short term safety of Belotero® Balance in the re-treatment of nasolabial folds.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Was a participant in the Belotero® Balance pre-market IDE clinical trial or the Belotero Balance Fitzpatrick Skin Type IV-VI Study.
- •Is a candidate for bilateral nasolabial fold re-treatment with Belotero® Balance.
- •Understands and accepts the obligation not to receive any other facial procedures from enrollment through 1 month from optimal correction in the current study.
- •Understands and accepts the obligation to comply with the required follow-up visits and is logistically able to meet all study requirements.
排除标准
- •Has received surgery in either nasolabial fold.
- •Has received within the past 6 months a non-permanent filler (e.g. hyaluronic acid, CaHA) or neurotoxin below the zygomatic arch.
- •Has received at any time a permanent filler (e.g. polylactic acid, PMMA, silicone) below the zygomatic arch.
- •Has received within the past 6 months dermal resurfacing procedures (e.g. medium/deep chemical peel, dermabrasion treatments, ablative laser resurfacing) or non-invasive skin-tightening (e.g. Thermage) below the zygomatic arch.
- •Has received in the past 2 weeks prescription facial wrinkle therapies (e.g., RENOVA®), topical steroids, skin irritating topical preparations, or pigmenting agents (self-tanning agents) below the zygomatic arch.
- •Has received in the past 2 months or plans to receive during the study immunosuppressive medications or systemic steroids (intranasal / inhaled steroids acceptable).
- •Has an acute inflammatory process or infection, or history of chronic or recurrent infection or inflammation with the potential to interfere with the study results or increase the risk of adverse events.
- •Has a known bleeding disorder or is using medication that reduces blood coagulation, (e.g. aspirin, non-steroidal anti-inflammatory drugs, or warfarin) which may increase the risk of bleeding during the treatment session.
- •Has a known history of severe allergies manifested by a history of anaphylaxis; or history or presence of multiple severe allergies.
- •Has known allergy or hypersensitivity to hyaluronic acid preparations, gram positive bacterial proteins or Belotero® or Belotero® derivative.
- •Has a known history of hyper- or hypo-pigmentation in the nasolabial folds, keloid formation, or hypertrophic scarring.
- •Is a female of childbearing potential (e.g. not post-menopausal for at least one year or has not had a hysterectomy or tubal ligation) and is pregnant, lactating or plans to become pregnant during the study or is not using medically effective birth control.
- •Has any other medical condition with the potential to interfere with the study or increase the risk of adverse events.
- •Is enrolled or plans to enroll in a competitive or interfering study.
- •Is an employee or direct relative of an employee of the investigational site or study sponsor.
- •All Fitzpatrick skin types are eligible for study participation
结局指标
主要结局
Rate of Severe Common Adverse Events
时间窗: 1 month
The purpose of this study was to determine if the rate of "Severe" common adverse events after re-treatment with Belotero Balance differs from the combined rates reported in the Belotero® Balance IDE clinical trial and Belotero® Balance Fitzpatrick Skin Type IV-VI Study (Pre-Approval Studies)."Common" is defined as pre-specified adverse events occurring in \>= 5% of study subjects. These averse events are: bruising, itching, pain, redness, swelling, discoloration, nodule, and induration.
次要结局
未报告次要终点
研究者
研究点 (9)
Loading locations...
相似试验
已完成
4 期
A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic MigraineMigraine DisordersNCT01516892Allergan716
终止
不适用
ORBERA365 Post-Marketing Clinical Follow-up StudyOverweightObesityNCT04362774Apollo Endosurgery, Inc.25
已完成
2 期
A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate CancerProstate NeoplasmsProstate CancerNCT01424930Janssen-Ortho Inc., Canada25
已完成
2 期
Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential ThrombocythemiaPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia MyelofibrosisPolycythemia VeraEssential ThrombocythemiaPrimary MyelofibrosisNCT02124746Sierra Oncology LLC - a GSK company87
进行中（未招募）
3 期
A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12)Pulmonary Arterial HypertensionPAHNCT04796337Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA815